Coronavirus- 4 Buy Stocks Now

Coronavirus- 4 Buy Stocks Now. The coronavirus has now gotten way out of control.
Globally, 78,442 people have been infected and more than 2.456 have already died. And, according to Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, “This new virus represents a tremendous public health threat.”
The World Health Organization (WHO) is warning of a shrinking window of opportunity to stop the spread of the deadly virus, as it spreads to 30 countries. “The window of opportunity is still there. But our window of opportunity is narrowing,” said WHO Director-General Tedros Adhanom Ghebreyesus. “We need to act quickly before it closes completely.”
However, there’s evidence the virus has become unstoppable.
According to CNN, Italy had more than 130 confirmed cases, which makes the region the hardest hit in Europe. It’s gotten so bad that towns and areas impacted by the virus in Italy have now been placed in lockdown.
Japan has 738 cases with three deaths. South Korea has 602 cases with five deaths. Singapore now has 89 deaths. Hong Kong has 74 cases and two deaths. There were another two deaths in Iran, with 13 new cases confirmed. In South Korea, the number of cases doubled in 24 hours, reaching 204. Australia confirmed six new cases.
As the issue grows worse, some of the top stocks to consider are:
Alpha Pro Tech (APT), which manufacturers masks and protective clothing, has seen its share price rocket from $3.60 to $6.40 in recent days.

Inovio Pharmaceuticals (INO) is also still gaining traction after receiving a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the coronavirus. Maxim Group analysts reiterated a buy rating on the stock with a near-term price target of $6.

Johnson & Johnson (JNJ) is an opportunity, as well. Racing against the clock, JNJ and the U.S. government recently expanded their partnership with regards to the virus.  Reportedly, the US will support the company’s attempt to develop antiviral drugs that can help people that already contracted the virus.

Even Gilead Sciences (GILD) is offering opportunity.  The company already started testing its antiviral remdesivir in patients with success.  Preliminary results from GILD’s clinical trials are expected in the next three weeks, says the World Health Organization.

For specific news event trades call Brad at 1-866-661-5664 or 1-310-647-5664

© 2020 Tradewins Publishing. All rights reserved.

The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by Ian Cooper a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk and is not appropriate for everyone. The actual profit results presented here may vary with the actual profit results presented in other Ian Cooper publications due to the different strategies and time frames presented in other publications. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, Ian Cooper does not make any guarantee or other promise as to any results that may be obtained from using the Services. Ian Cooper disclaims any and all liability for any investment or trading loss sustained by a subscriber. You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses.

Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Ian Cooper makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. No representation is being made that you will achieve profits or the same results as any person providing a testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have subsequently experienced losses. Ian Cooper ‘s experiences are not typical. Ian Cooper is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position, willingness to follow the rules and other factors